myAACR
Donate Today
Skip to Content

Progress Against Cancer

Home Patients, Caregivers, and Advocates Progress Against Cancer Research

Recent Progress: FDA Approvals

First-line Immunotherapy for Stomach Cancer

First-line Immunotherapy for Stomach Cancer

The FDA has approved pembrolizumab for the first-line treatment of certain HER2-negative gastric and gastroesophageal junction cancers.  The U.S. Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda), in combination with a chemotherapy regimen...